Our Therapeutic Areas
Gilead is committed to advancing care for people around the world, by bringing forward medicines in areas of unmet medical need. We do this through internal research and development, as well as through collaborations with academic and industry partners.
Since 1987, Gilead has delivered more than 25 innovative medicines, helping to improve treatment for people living with diseases such as HIV, viral hepatitis, cancer and other conditions.
Gilead has helped transform care for people living with and at risk of HIV, pioneering inventions that were once thought impossible, such as the first single tablet regimen to treat HIV.
Our work in HIV continues to span the full continuum of HIV care – from prevention to treatment to working toward the goal of a cure. We are committed to a goal of offering options that can help address the differentiated needs and preferences of the diverse range of people living with and at risk for HIV. Beyond the science, we collaborate with partners to help address the root causes driving the HIV epidemic. We are working to ensure that people living with HIV, and those at risk of infection, have access to care and treatment.
Hepatitis C, B and D Viruses
With the same tenacity, innovation and focus that drove our work in HIV, we delivered four treatments for chronic hepatitis C virus in less than four years. Today, more than 4 million people have been prescribed our HCV medicines and we continue to reach more people around the world. We have also been on the front lines of transforming care for people with chronic hepatitis B virus for 20 years and are actively pursuing multiple pathways toward a possible cure. In 2021, through the acquisition of MYR GmbH, we built on our strength in this area.
Innovating to Treat COVID-19
When the COVID-19 outbreak began to emerge, we responded quickly to advance our then-investigational antiviral which had shown potential against other coronaviruses in laboratory and preclinical experiments, deploying decades of antiviral expertise and significant internal resources to help patients and communities working to ease the burden of the pandemic. Today, more than 10 million people globally have received our COVID-19 treatment. Gilead also signed non-exclusive voluntary licensing agreements with generic manufacturers to further expand supply of the product for distribution in 125+ countries, nearly all of which are resource limited.
Improving Outcomes for People Living with Cancer
Significant investments have been made by Gilead to add to our oncology portfolio. Our approach covers a broad range of tumour types, including haematological malignancies and solid tumours. We are working to deliver these medicines to patients in need as quickly as possible.
With the acquisition of Immunomedics, we added our first therapy for solid tumours. Our colleagues at Kite are responsible for the research, development and commercialisation of our cell therapies.
Developing Innovative Therapies for Inflammation
Gilead is researching new treatments and advancing care to help people living with a range of inflammatory diseases live healthier lives, including diseases such as inflammatory bowel disease and lupus. We are also putting our expertise to work to advance scientific understanding and investigational medicines for complex and difficult to treat fibrotic diseases such as nonalcoholic steatohepatitis and primary sclerosing cholangitis.
A Historical Commitment Against Invasive Fungal Infections
For 30 years, Gilead has been investing in the treatment of invasive fungal infections, in particular aspergillosis, candidiasis, visceral leishmaniasis (VL) and cryptococcal meningitis. Gilead continues to work to improve access to antifungal treatments for all people in need.